pharma QA – Page 85 – Pharma.Tips

Phase Separation at accelerated stability: investigation steps with CAPA evidence

Steps to Investigate Phase Separation at Accelerated Stability in Otic Dosage Forms Phase separation in otic dosage forms during accelerated stability testing can indicate potential quality failures, leading to Out…

Assay Oos at accelerated stability: GMP investigation steps with CAPA

Addressing Assay OOS in Accelerated Stability: Comprehensive GMP Investigation Steps In the realm of pharmaceutical manufacturing, deviations during quality control testing, specifically Out of Specification (OOS) results, can lead to…

Microbial Limits Failure in dental gel manufacturing: GMP investigation steps with CAPA

GMP Investigation Steps for Microbial Limits Failure in Dental Gel Manufacturing The pharmaceutical industry faces stringent requirements for microbial limits in manufacturing operations, particularly within dental gel formulations. A microbial…

Texture Grittiness Complaint at accelerated stability: packaging compatibility and shelf-life justification

Investigating Texture Grittiness Complaints During Accelerated Stability Testing The integrity of pharmaceutical products is paramount, and complaints regarding texture grittiness during accelerated stability can pose significant challenges in manufacturing and…

Fill Volume Variability during method transfer: investigation steps with CAPA evidence

Investigating Fill Volume Variability during Method Transfer in Pharmaceutical Manufacturing Fill volume variability during method transfer is a critical quality issue that may lead to non-conformance with product specifications. Pharmaceutical…

Assay Oos in dental paste filling: GMP investigation steps with CAPA

GMP Investigation Steps for Assay OOS in Dental Paste Filling Operational issues with assay Out of Specification (OOS) results in dental paste filling can significantly hinder production processes, resulting in…

Microbial Limits Failure at accelerated stability: GMP investigation steps with CAPA

Investigation Steps for Microbial Limits Failure at Accelerated Stability Testing Microbial limits failure during accelerated stability testing can pose significant challenges in pharmaceutical manufacturing and quality assurance. This scenario not…

Media Fill Failure at stability pull: sampling, filtration, and EM controls

Understanding Media Fill Failures during Stability Pulls: An Investigation Approach Media fill failures can pose significant challenges during the stability pull phase in pharmaceutical manufacturing, particularly in ophthalmic dosage forms.…

Texture Grittiness Complaint in dental paste filling: QMS trending and complaint handling expectations

Handling Texture Grittiness Complaints in Dental Paste Filling: A Structured Investigation Approach Texture grittiness complaints in dental paste fillings can significantly impact product quality and patient satisfaction, necessitating a thorough…

Viscosity Drift after packaging change: manufacturing vs lab root cause assessment

Assessing Viscosity Drift Following a Packaging Change: Root Cause Investigation in Pharma Manufacturing Recently, a manufacturing facility encountered repeated viscosity drift in dental dosage forms following a change in packaging…

Fill Weight Variability after packaging change: QMS trending and complaint handling expectations

Addressing Variability in Fill Weight Post-Packaging Change: A Comprehensive Investigation Approach Fill weight variability following a packaging change is a significant concern in pharmaceutical manufacturing, especially for dental dosage forms…

Ccit Failure after packaging change: packaging integrity and CCIT justification

Ccit Failures Following a Packaging Change: Understanding Integrity and Justification In the pharmaceutical manufacturing industry, the stability and quality of dosage forms are paramount. A CCIT (Container Closure Integrity Testing)…